TableĀ 2

Selected translational research priorities from the EMBARC roadmap [19]

Key translational research questionsRecommendations
What causes bronchiectasis?DNA biobanks linked to well-phenotyped patient cohorts should be established to enable underlying genetic susceptibility to bronchiectasis to be established.
What causes bronchiectasis exacerbations?A comprehensive study enrolling patients when stable and during exacerbation should be conducted, evaluating the impact of bacteria, viruses, fungi and noninfectious stimuli to identify the cause(s) of bronchiectasis exacerbations.
Development of new therapies and biomarkersA deeper understanding of the inflammatory pathways in bronchiectasis is needed to develop new therapies. We recommend using emerging techniques and technologies (particularly proteomics, metabolomics and genomics) in large, well-characterised cohorts to identify new treatment targets and deeper patient phenotyping.
How does the microbiome impact patient outcomes in bronchiectasis?We suggest studies of the microbiome (incorporating bacteria and potentially fungi) in bronchiectasis linked to detailed clinical phenotyping data.
Why do some patients become infected with Pseudomonas aeruginosa?Mechanistic studies investigating the genetic, microbiological, inflammatory and clinical susceptibility factors for P. aeruginosa colonisation should be conducted.